<p>Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. Here we use next-generation sequencing technologies to characterize the genomic and transcriptomic features of CAR-T cells and tumors that influence therapeutic responses. Please see our submission to NCBI GEO (<a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273170">GSE273170</a>) for additional data. </p>

Genomic and Transcriptomic Sequencing of CAR-T-Treated Patients

Lymphoma, B-Cell study with OTHER data on dbGaP (58 participants)